With all the attention-grabbing headlines out there, don't forget about the Treasury auction, CPI data and these other critical issues.
For Pfizer, China is third largest market and a growing area of concern.
Try this buy-write strategy to get a piece of PFE on its headline-grabbing news.
This is likely to be quickly forgotten again and the focus turn to earnings.
Cloud and defense are still looking good, but watch out for retail names.
Maybe the worries are well justified but this market just doesn't care right now.
He is focused on curtailing the power of regulators, agencies and government.
Bad news just can't seem to kill an aging bull market.
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.